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Abstract²Starting from compound 1, we utilized biostructural data to successfully evolve an existing series into a new chemotyope with 
a promising overall profile, exemplified by X.  
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The D-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptors belong to the family 
of ionotropic glutamate ion channels. These receptor 
complexes are widely expressed in the central nervous 
system and are considered to mediate the majority of 
fast excitatory amino acid neurotransmission.[1] The 
role of AMPA receptors appears to be crucial to 
facilitating synaptic plasticity and long-term 
potentiation (LTP), the use dependent enhancement in 
synaptic efficacy which is believed to underlie various 
forms of learning and memory. AMPA receptor 
modulators have been shown to enhance LTP and are, 
therefore, under serious consideration as therapeutic 
agents for a range of neurological disorders including 
VFKL]RSKUHQLD $O]KHLPHU¶V 'LVHDVH 3DUNLQVRQ¶V
disease and ADHD.[2,3] 
 
Our earlier work described the identification of 1 
through optimization of an HTS derived hit.[4,5] Key 
properties associated with compound 1 and its X-ray co-
crystal structure in complex with the S1S2 Ligand 
Binding Domain (LBD) GluA2 construct is depicted in 
Figure 1. [6] 
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Figure 1. Lead compound 1, summary property data & structure in 
complex with the GluA2 S1S2 LBD. As the binding site spans an 
intramolecular two-axis, two orientations of 1 are observed in the crystal 
structure, but only one is shown here for clarity. 
 
In order to identify a new chemotype as a potential 
back-up series to that exemplified by 1, we sought to 
leverage literature data through exploiting our 
knowledge of the binding mode of our existing leads. 
 The basic strategy adopted is delineated in Figure 2. 
 
 
 
 
 
 
 
 
 
 
Figure 2. Lead series evolution through hybridization with literature 
compounds. 
 
Compound 2, a hydroxyl containing analogue of 1 was 
considered to be a synthetically more expedient starting 
point and was shown to have similar potency and 
solubility (GluA1 pEC50 = 6.4, solubility = 20 mg/L).  
We proposed to hybridize 2 with LY404187 (3) a 
AMPA receptor modulator which had previously been 
reported in the literature. [7] In addition, the X-ray co-
crystal structure of 3 was known [8], thus facilitating 
detailed knowledge of how the compound interacted 
with the receptor.  Preparation and subsequent 
characterization of 4 indicated that the hybridized 
compound retained an acceptable balance of potency 
and solubility. 
 
In vitro, compound 4 was shown to have excellent 
microsomal stability (rat Cli < 12 PL/min/mg protein, 
human Cli <12 PL/min/mg protein) and reasonable 
permeability in a CaCo-2 assay, with no evidence of 
efflux (A-B = 206 nm/s, B-A = 287 nm/s). However, in 
vivo pharmacokinetic data was less promising (Clp = 
49.7 mL/min/kg; T1/2 = 1.0h; F% = 3.2; 1 mg/kg dose 
(i.v.), 5 mg/kg (p.o.) using Wistar BRL rats). We 
hypothesized that improvement in oral bioavailability of 
4 could be achieved through lowering clearance. 
Therefore, we considered conformational constraint of 4 
with the expectation of being able to negate 
conformations predisposed to metabolism by CYP P450 
enzymes.  At the same time, we became aware of a 
related series of AMPA receptor modulators represented 
by 5 (Figure 3) [9] and thus sought to leverage these in 
our strategy of constraining our ligands. 
 
Disappointingly, evaluation of 6 in the GluA2 
functional assay indicated that the compound had only  
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3. Introduction of conformational restraint. 
 
weak activity as an AMPA receptor modulator (pEC50 
< 4.5).  However, from consideration of the X-ray data 
of 4 in complex with the GluA2 S1S2 LBD, indicated 
that the pyrazole moiety did not interact with the 
receptor, which was in contrast with progenitor 
compounds such as 1 (Figure 4). In particular, the 
pendant trifluoromethyl group was not able to 
participate in a hydrophobic interaction with the 
receptor. We reasoned that insertion of a methylene 
spacer between the pyrazole group and central phenyl 
ring would be sufficient to restore this missing 
interaction. Preparation and testing of compound 7 
(GluA2 pEC50 = 6.3) confirmed our hypothesis and 
further confirmation was provided upon solution of the 
X-ray co-complex of 7 with the GluA2 S1S2 LBD 
(Figure 4). 
 
 
Figure 4. Overlaid X-ray structure of compounds 4 and 7 in complex 
with the GluA2 S1S2 LBD. 
 
Compound 7 was shown to have good microsomal 
stability (rat Cli 31 PL/min/mg protein, human Cli 23 
PL/min/mg protein) and reasonable permeability in a 
CaCo-2 assay, albeit with some suggestion of efflux (A-
B = 128 nm/s, B-A = 290 nm/s). Pleasingly, in vivo 
pharmacokinetic data was vastly superior when 
compared to compound 4, with improved clearance and 
oral bioavailability. (Clp = 21.6 mL/min/kg; T1/2 = 2.9h; 
F% = 94; 1 mg/kg dose (i.v.), 5 mg/kg (p.o.) using 
Wistar BRL rats).  
 
Having suitably benchmarked compound 7, our 
attention then turned to generation of SAR within this 
constrained series. Our initial focus was in the pyrazole 
region which proved to be quite flexible in terms of 
which modifications were tolerated (Table 1). 
 
Table 1. Exploration of pyrazole region. 
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aValues are means of two experiments performed in duplicate.  
 
Replacement (8) or homologation (9) of the pendant 
alcohol moiety had a minimal impact on potency. 
Similarly, incorporation of fragments (compounds 10 to 
12) from our previously reported lead series [4,5] was 
reasonably well tolerated, with compound 12 gaining 
additional potency, albeit at the expense of solubility (< 
1mg/L).  The isomeric pyrazole system 13 was 
approximately ten-fold less potent, and this was 
attributed to the trifluoromethyl group being unable to 
make the same close hydrophobic contact with the 
receptor as in compound 7. The C-linked pyrazole 
system in compound 14 was also of similar potency 
compared to the progenitor compound as was the 
pyrrole based moiety 15.  Similarly, the furan derived 
system 16 demonstrated that diversification away from 
the original pyrazole motif could be achieved.  
Compound 16 was shown to bind to the receptor in a 
similar manner to 7, with the trifluromethyl group 
making a hydrophobic interaction with the receptor 
(Figure 5). 
 
 
 
Figure 5. X-ray structure of compound 16 in complex with the S1S2J 
LBD of GluA2. 
 
 
Having explored the pyrazole region of 7, we 
subsequently focused on the indane sulfonamide portion 
of the molecule (Table 2). 
 
Table 2. SAR exploration of indane sulfonamide region. 
 
 
 
 
Compds Position Stereochem R pEC50
a 
7 2 S iPr 6.3 
17 2 R iPr 6.4 
18 2 S CF3 5.3 
19 2 R CF3 5.6 
20 2 R cPr 5.6 
21 2 R NMe2 6.0 
22 2 S Et 6.4 
23 2 S Me 5.1 
24 1 rac iPr 7.0 
25 1 rac cPr 6.8 
26 1 rac Me 6.3 
27 1 rac 
 
5.7 
28 1 rac 
 
5.9 
aValues are means of two experiments performed in duplicate.  
 
Comparing enantiomeric pairs such as compounds 7 & 
17 and compounds 18 & 19 suggested that no distinct 
stereochemical preference existed within the series. 
Modification to the pendant isopropyl group was largely 
tolerated (19-23), although activity began to diminish 
when the size of the substituent was reduced (c.f. 22 and 
23).  Examination of the X-ray co-crystal structure of 7 
points to the isopropyl group on the sulfonamide 
making a hydrophobic interaction with the receptor 
which accounts for the trend observed. Substitution 
from the 1-position of the indanyl system resulted in an 
increase in potency (24) and related analogues (25, 26) 
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 demonstrated a degree of flexibility in the SAR of this 
region, with aryl substituted sulfonamide derivatives 
being tolerated also (27, 28). 
 
Following additional profiling of a number of 
compounds in the series, compound 19 emerged as 
having the best overall balance of potency and 
developability properties.  These are summarized in 
Table 3. 
 
Table 3. Developability properties of 19 
 
Property  
 
 
 
Solubility 
(mg.L-1) 
84 
Microsomal stability 
(Clint, µg.min-1.mg-1) 
<12 (rat) 
<12 (human) 
Hepatocyte stability 
(Clint, µl.min-1.Mcells-1)  
<6 (rat) 
 
Caco2 
(nm.s-1)  
169(A-B ) 
264 (B-A)  
 
Rat PKa,b CL= 1.9 ml/(min.kg) 
Vss= 1.0 L/kg 
T½= 7.4h F% = 100 
Cmax Rat CSF
c 
 
0.12PM 
a 2 mg/kg i.v. dose Wistar BRL rats; b 10 mg/kg p.o. dose Wistar BRL 
rats; c 2 mg/kg i.p. dose Wistar BRL rats. 
 
Compound 19 displayed high aqueous solubility and 
excellent stability in both microsomal and hepatocyte 
preparations.  Permeability was predicted to be good 
from the CaCo-2 assay, with little evidence of efflux 
and this was mirrored in vivo with excellent oral 
bioavailability observed, along with low clearance and 
highly encouraging half life.  CNS exposure was 
determined through measurement of drug concentration 
in CSF. This study showed good exposure and 
concentrations equivalent to the free drug in plasma, 
suggesting no efflux from the CNS. [10] 
 
Synthesis of the compounds described above is outlined 
in Schemes 1 to 6. Sulfonylation of 29 (Scheme 1) 
followed by iodination and subsequent copper mediated 
arylation furnished 32. Reduction with LiAlH4 gave 
target compound 4. Compound 6 was accessed in an 
analogous fashion as illustrated in Scheme 2.  
 
Compounds 7-11 were prepared as outlined in Scheme 
3. Bromination of 2-aminoindane followed by 
resolution11 gave enantiomerically pure amine 40. 
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Scheme 1. Reagents and conditions: a) iPrSO2Cl, Et3N, DMAP, CH2Cl2, 
r.t., 87%; b) I2, H2SO4, AcOH, H5IO6, H2O, 5 °C, 70%; c) ethyl-3-
(trifluoromethyl)pyrazole-4-carboxylate, CuI, N,N-dimethylcyclohexane-
1,2-diamine, K2CO3, PhMe, 110 °C, 40%; d) LiAlH4, THF, r.t., 52%. 
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Scheme 2. Reagents and conditions: a) iPrSO2Cl, DBU, CH2Cl2, r.t., 
88%; b) I2, H2SO4, AcOH, H5IO6, H2O, 5 °C, 56%; c) ethyl-3-
(trifluoromethyl)pyrazole-4-carboxylate, CuI, N,N-dimethylcyclohexane-
1,2-diamine, K2CO3, PhMe, 110 °C, 16%; d) LiAlH4, THF, r.t., 88%. 
 
Sulfonylation followed by palladium mediated 
carbonylation and reduction gave alcohol 43 which 
could then be chlorinated and used to alkylate the 
appropriate azole derivative. Compound 8 was obtained 
directly from 7 by treatment with DAST, while 
compound 13 could be obtained via careful 
chromatographic separation from 7. 
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Scheme 3. Reagents and conditions: a) Br2, H2O, 60 °C, 56%; b) L-
camphorsulfonic acid, NMO, MeOH, 65°C, 26%; c) iPrSO2Cl, DBU, 
CH2Cl2, 0°C, 93%; d) acetoxy(2-(dio-tolylphosphino)benzyl)palladium, 
PtBu3.HBF4, DBU, MeCN/MeOH, 150 °C, PW, 88%; e) LiAlH4, THF, 
0°C, 100%; f) SOCl2, CH2Cl2, r.t., 100%; g) azole derivative, NaH, DMF, 
60 °C, 19-55%; i) DAST, CH2Cl2, 20%. 
 
Scheme 4 outlines the preparation of analogues 14 and 
16. The boronate ester 45 was prepared and used in a 
palladium catalysed sp2-sp3 coupling [12] to furnish 
both target compounds. 
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Scheme 4. Reagents and conditions: a) bis(pincolato)diboron, 
Pd(dppf)Cl2, KOAc, DMF, 60 °C, 41%; b) HetCH2Cl, Pd2(dba)3.CHCl3 
complex, PPh3, NBS, Na2CO3, 100 °C, PW, 16-20%. 
 
Sulfonamide derivatives 17 to 23 were prepared 
according to the synthetic plan delineated in Scheme 5. 
Resolution of aminoindane 39 with either L- or D-CSA 
gave (S) or (R) enantiomers, respectively. Cbz 
protection followed by carbonylation and subsequent 
reduction gave 50a/50b as separate compounds, both of 
which could be converted to the chloride derivative and 
used to alkylate the requisite pyrazole alcohol. 
Protecting group removal followed by the final diversity 
step gave target compounds 17-23 as discrete 
enantiomers. 
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Scheme 5. Reagents and conditions: a) D or L-camphorsulfonic acid, 
NMO, MeOH, 65°C, 26-30%; b) benzyl chlorformate, K2CO3, 
EtOAc/water; 100%; c) acetoxy(2-(dio-tolylphosphino)benzyl)palladium, 
PtBu3.HBF4, DBU, MeCN/MeOH, 150 °C, PW, 89-93%; d) LiBH4, THF, 
r.t., 48-51%; e) i. SOCl2, CH2Cl2, r.t. ii. (3-(trifluoromethyl)-1H-
pyrazolyl-4-yl)methanol, K2CO3, 60 °C, 77-81% (over 2 steps); f) 
Pd(OH)2, EtOH/5N HCl, H2 (2bar), 66-71%; g) sulfonyl chloride 
derivative or (CF3SO2)2O (for 18 & 19), Et3N, CH2Cl2, 17-71%. 
 
Compounds 24 to 28 were prepared in an analogous 
fashion to the above starting from 5-bromo-2,3-dihydro-
1H-inden-amine (53) which is prepared through via 
reduction of an oxime intermediate derived from 5-
bromoindan-1-one (52, Scheme 6). 
 
In summary, this work has that key component of our 
scaffold hopping strategy has been the application of 
SBDD against an ion channel targe in directing our 
template modifications as well as offering key insights 
into SAR within the series. Starting from a lead 
compound 1, we have demonstrated how this can be 
optimized to yield a structurally differentiated entity 
(19) with an excellent overall balance of properties. We 
believe 19 will be a valuable tool in further 
understanding the role of AMPA receptor modulators in 
complex neurological disorders. 
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Scheme 5. Reagents and conditions: a) i. NH2OH.HCl, EtOH, reflux ii. 
Zn, AcOH, r.t. 68% (over 2 steps) b) benzyl chlorformate, K2CO3, 
EtOAc/water; 67%; c) acetoxy(2-(dio-tolylphosphino)benzyl)palladium, 
PtBu3.HBF4, DBU, MeCN/MeOH, 150 °C, PW, 77%; d) LiAlH4, THF, 
r.t., 48%; e) i. SOCl2, CH2Cl2, r.t. ii. Ethyl (3-(trifluoromethyl)-1H-
pyrazolyl-4-yl)carboxylate, K2CO3, 60 °C, 84% (over 2 steps); f) LiAlH4, 
THF, r.t., 74% g) Pd(OH)2, EtOH/5N HCl, H2 (2bar), 83%; h) sulfonyl 
chloride derivative, Et3N, CH2Cl2, 24-32%. 
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